1. Home
  2. NVNI vs ATNM Comparison

NVNI vs ATNM Comparison

Compare NVNI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

N/A

Current Price

$1.31

Market Cap

12.9M

Sector

N/A

ML Signal

N/A

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

N/A

Current Price

$1.18

Market Cap

36.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVNI
ATNM
Founded
2019
2000
Country
Brazil
United States
Employees
618
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
36.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
NVNI
ATNM
Price
$1.31
$1.18
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
83.8K
109.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.60
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$1.02
52 Week High
$4.94
$1.95

Technical Indicators

Market Signals
Indicator
NVNI
ATNM
Relative Strength Index (RSI) 37.97 48.69
Support Level $1.10 $1.02
Resistance Level $1.64 $1.71
Average True Range (ATR) 0.14 0.07
MACD 0.04 0.02
Stochastic Oscillator 40.00 62.79

Price Performance

Historical Comparison
NVNI
ATNM

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: